GlassScriptPhysician profile
Alexander K Choi
NPI 1104818640
$5,994.30
in general payments reported to CMS, 2019-2025
27 companies · $95.10 in 2025
The $95.10 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,227 · 2020: $856 · 2021: $984 · 2022: $1,560 · 2023: $1,202 · 2024: $70.37 · 2025: $95.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,367.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,075.53 | 2022-2025 | Xeomin |
| Abbvie INC. | $824.13 | 2019-2023 | Linzess, Viberzi, Creon |
| Amarin Pharma, INC. | $780.15 | 2019-2023 | |
| Lilly USA, LLC | $709.52 | 2019-2023 | Mounjaro, Jardiance |
| Novo Nordisk INC | $507.13 | 2020-2023 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $370.33 | 2019-2022 | |
| Amgen INC. | $217.86 | 2019-2023 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $197.05 | 2019-2022 | |
| Astellas Pharma US INC | $189.07 | 2019-2023 | Myrbetriq, Veozah |
| Glaxosmithkline, LLC. | $168.52 | 2019-2023 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $149.61 | 2019-2021 | |
| Pfizer INC. | $134.94 | 2019-2020 | |
| Microvention, INC. | $112.29 | 2019 | |
| Insmed, INC. | $109.34 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.81 | 2022-2023 | Trintellix |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.98 | 2019-2021 | |
| Sanofi Pasteur INC. | $64.65 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $39.06 | 2021 | |
| Allergan, INC. | $38.44 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $30.61 | 2025 | |
| Vbi Vaccine (Delaware) INC. | $27.35 | 2022 | |
| Gilead Sciences, INC. | $25.58 | 2019 | |
| Arbor Pharmaceuticals, INC. | $22.23 | 2021 | |
| Nestle Healthcare Nutrition INC. | $21.69 | 2023 | |
| Esperion Therapeutics, INC. | $18.45 | 2021 | |
| Vivus LLC | $18.00 | 2021 | |
| Avanir Pharmaceuticals, INC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.